KALA BIO, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KALA Nasdaq 2836 www.kalarx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for KALA BIO, Inc.

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - Oct 8th, 2025 9:18 am
Top Midday Decliners - Sep 30th, 2025 12:22 pm
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Sep 29th, 2025 6:00 am
KALA BIO, Inc.'s (NASDAQ:KALA) market cap surged US$28m last week, retail investors who have a lot riding on the company were rewarded - Sep 5th, 2025 4:20 am
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 6:00 am
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director - Sep 2nd, 2025 6:00 am
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade - Aug 13th, 2025 7:55 am
KALA BIO: Q2 Earnings Snapshot - Aug 8th, 2025 6:08 am
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 8th, 2025 6:00 am
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - Aug 6th, 2025 6:00 am
Zacks.com featured highlights include KALA, Graham, Arq and Hawkins - Jul 28th, 2025 6:23 am
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility - Jul 25th, 2025 9:55 am
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Jul 9th, 2025 6:00 am
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Jul 7th, 2025 6:00 am
KALA BIO to Present at Jefferies Global Healthcare Conference - May 29th, 2025 6:00 am
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 14th, 2025 6:00 am
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Mar 31st, 2025 6:00 am
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference - Feb 26th, 2025 6:00 am
KALA BIO Announces Chief Executive Officer Transition - Feb 12th, 2025 6:00 am
KALA BIO Announces $10,750,000 Private Placement - Dec 30th, 2024 6:00 am